333 related articles for article (PubMed ID: 17552048)
1. Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis.
Visvanathan S; Marini JC; Smolen JS; Clair EW; Pritchard C; Shergy W; Pendley C; Baker D; Bala M; Gathany T; Han J; Wagner C
J Rheumatol; 2007 Jul; 34(7):1465-74. PubMed ID: 17552048
[TBL] [Abstract][Full Text] [Related]
2. Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials.
Doyle MK; Rahman MU; Han C; Han J; Giles J; Bingham CO; Bathon J
Semin Arthritis Rheum; 2009 Oct; 39(2):123-31. PubMed ID: 18823645
[TBL] [Abstract][Full Text] [Related]
3. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone.
Durez P; Malghem J; Nzeusseu Toukap A; Depresseux G; Lauwerys BR; Westhovens R; Luyten FP; Corluy L; Houssiau FA; Verschueren P
Arthritis Rheum; 2007 Dec; 56(12):3919-27. PubMed ID: 18050189
[TBL] [Abstract][Full Text] [Related]
4. IgG and IgM anticardiolipin antibodies following treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis.
Visvanathan S; Wagner C; Smolen J; St Clair EW; Hegedus R; Baker D; Keenan G
Arthritis Rheum; 2006 Sep; 54(9):2840-4. PubMed ID: 16948115
[TBL] [Abstract][Full Text] [Related]
5. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
Quinn MA; Conaghan PG; O'Connor PJ; Karim Z; Greenstein A; Brown A; Brown C; Fraser A; Jarret S; Emery P
Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
[TBL] [Abstract][Full Text] [Related]
6. Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial.
Fleischmann RM; Cohen SB; Moreland LW; Schiff M; Mease PJ; Smith DB; Keenan G; Kremer JM;
Curr Med Res Opin; 2005 Aug; 21(8):1181-90. PubMed ID: 16083527
[TBL] [Abstract][Full Text] [Related]
7. Treatment of early seropositive rheumatoid arthritis: doxycycline plus methotrexate versus methotrexate alone.
O'Dell JR; Elliott JR; Mallek JA; Mikuls TR; Weaver CA; Glickstein S; Blakely KM; Hausch R; Leff RD
Arthritis Rheum; 2006 Feb; 54(2):621-7. PubMed ID: 16447240
[TBL] [Abstract][Full Text] [Related]
8. Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone.
Visvanathan S; Keenan GF; Baker DG; Levinson AI; Wagner CL
J Rheumatol; 2007 May; 34(5):952-7. PubMed ID: 17444589
[TBL] [Abstract][Full Text] [Related]
9. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
Smolen JS; Han C; Bala M; Maini RN; Kalden JR; van der Heijde D; Breedveld FC; Furst DE; Lipsky PE;
Arthritis Rheum; 2005 Apr; 52(4):1020-30. PubMed ID: 15818697
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
Maini RN; Breedveld FC; Kalden JR; Smolen JS; Davis D; Macfarlane JD; Antoni C; Leeb B; Elliott MJ; Woody JN; Schaible TF; Feldmann M
Arthritis Rheum; 1998 Sep; 41(9):1552-63. PubMed ID: 9751087
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
Seitz M; Zwicker M; Villiger PM
J Rheumatol; 2003 Jan; 30(1):28-35. PubMed ID: 12508386
[TBL] [Abstract][Full Text] [Related]
12. The effect of infliximab on bone metabolism markers in patients with rheumatoid arthritis.
Torikai E; Kageyama Y; Takahashi M; Suzuki M; Ichikawa T; Nagafusa T; Nagano A
Rheumatology (Oxford); 2006 Jun; 45(6):761-4. PubMed ID: 16436492
[TBL] [Abstract][Full Text] [Related]
13. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab.
Lequerré T; Jouen F; Brazier M; Clayssens S; Klemmer N; Ménard JF; Mejjad O; Daragon A; Tron F; Le Loët X; Vittecoq O
Rheumatology (Oxford); 2007 Mar; 46(3):446-53. PubMed ID: 16899502
[TBL] [Abstract][Full Text] [Related]
14. Infliximab treatment maintains employability in patients with early rheumatoid arthritis.
Smolen JS; Han C; van der Heijde D; Emery P; Bathon JM; Keystone E; Kalden JR; Schiff M; Bala M; Baker D; Han J; Maini RN; St Clair EW
Arthritis Rheum; 2006 Mar; 54(3):716-22. PubMed ID: 16508932
[TBL] [Abstract][Full Text] [Related]
15. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.
Kavanaugh A; St Clair EW; McCune WJ; Braakman T; Lipsky P
J Rheumatol; 2000 Apr; 27(4):841-50. PubMed ID: 10782805
[TBL] [Abstract][Full Text] [Related]
16. A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis.
Abe T; Takeuchi T; Miyasaka N; Hashimoto H; Kondo H; Ichikawa Y; Nagaya I
J Rheumatol; 2006 Jan; 33(1):37-44. PubMed ID: 16395748
[TBL] [Abstract][Full Text] [Related]
17. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis.
Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
J Rheumatol; 2004 Feb; 31(2):238-42. PubMed ID: 14760791
[TBL] [Abstract][Full Text] [Related]
18. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement.
Alessandri C; Bombardieri M; Papa N; Cinquini M; Magrini L; Tincani A; Valesini G
Ann Rheum Dis; 2004 Oct; 63(10):1218-21. PubMed ID: 15361374
[TBL] [Abstract][Full Text] [Related]
19. A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment.
Durez P; Nzeusseu Toukap A; Lauwerys BR; Manicourt DH; Verschueren P; Westhovens R; Devogelaer JP; Houssiau FA
Ann Rheum Dis; 2004 Sep; 63(9):1069-74. PubMed ID: 15308515
[TBL] [Abstract][Full Text] [Related]
20. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis.
Shergy WJ; Isern RA; Cooley DA; Harshbarger JL; Huffstutter JE; Hughes GM; Spencer-Smith EA; Goldman AL; Roth SH; Toder JS; Warner D; Quinn A; Keenan GF; Schaible TF;
J Rheumatol; 2002 Apr; 29(4):667-77. PubMed ID: 11950005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
